Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 58 min 50 sec ago

Ember Therapeutics Enhances Regenerative Medicine Pipeline With Acquisition of ICX-RHY/Vavelta(TM) from Intercytex

Wed, 03/16/2016 - 21:01
NEW YORK, March 16, 2016 -- (Healthcare Sales & Marketing Network) -- Ember Therapeutics, Inc. (EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogene...
Regenerative Medicine, Dermatology, Acquisitions
Ember Therapeutics, Intercytex, ICX-RHY, Vavelta, dermal fibroblast

Ember Therapeutics Enhances Regenerative Medicine Pipeline With Acquisition of ICX-RHY/Vavelta(TM) from Intercytex

Wed, 03/16/2016 - 16:42
NEW YORK, March 16, 2016 -- (Healthcare Sales & Marketing Network) -- Ember Therapeutics, Inc. (EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogene...
Regenerative Medicine, Dermatology, Acquisitions
Ember Therapeutics, Intercytex, ICX-RHY, Vavelta, dermal fibroblast

Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults

Wed, 03/16/2016 - 16:38
DUBLIN, March 16, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, announced today that VRAYLAR™ (cariprazine), a once-daily oral atypical antipsychotic, is now available by prescription in pha...
Biopharmaceuticals, Product Launch
Allergan, VRAYLAR, cariprazine, Bipolar Mania, Schizophrenia

Abbott's Absorb(TM), the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee

Wed, 03/16/2016 - 16:33
Panel of Independent Experts Reviewed Clinical Data Supporting the Safety and Efficacy of the Absorb Device Compared to the Market-Leading Metallic Drug Eluting Stent Currently Available in More Than 100 Countries, the Absorb Bioresorbable Stent Has Bee...
Devices, Interventional, Cardiology, FDA
Abbott, Absorb stent, coronary stent, everolimus

CardiacAssist Receives FDA 510(k) Clearance For Its TandemLung Oxygenator

Tue, 03/15/2016 - 16:39
TandemLung is the newest addition to an expanding portfolio of medical devices offered by the manufacturer of the world's first percutaneous circulatory support platform PITTSBURGH, March 15, 2016 -- (Healthcare Sales & Marketing Network) -- CardiacAss...
Devices, FDA
CardiacAssist, TandemLung, TandemHeart, extracorporeal life support

Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study

Tue, 03/15/2016 - 16:33
INDIANAPOLIS, March 15, 2016 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) today announced a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's demen...
Biopharmaceuticals, Neurology
Eli Lilly, solanezumab, Alzheimer's

Heart Metabolics Announces Multiple Senior Appointments To Management Team

Tue, 03/15/2016 - 16:29
All functional areas strengthened to support advancement of the clinical pipeline DUBLIN and SAN FRANCISCO, March 15, 2016 -- (Healthcare Sales & Marketing Network) -- Heart Metabolics Limited (Heart Metabolics), a biotechnology company focused on the ...
Biopharmaceuticals, Cardiology, Personnel
Heart Metabolics, perhexiline, Hypertrophic Cardiomyopathy

CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors

Tue, 03/15/2016 - 16:27
CAMBRIDGE, Mass., March 15, 2016 -- (Healthcare Sales & Marketing Network) -- CoLucid Pharmaceuticals, Inc. (CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of mig...
Biopharmaceuticals, Personnel
CoLucid Pharmaceuticals, lasmiditan, migraine

Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States

Tue, 03/15/2016 - 16:18
Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets Takeda Moves to Strengthen Focus on Recent Launches SAN DIEGO and DEERFIELD, Ill., and OSAKA, Japan, March 15, 2016 -- (Healthcare Sales & Marketing Network) -- Ore...
Biopharmaceuticals, Acquisitions
Orexigen Therapeutics, Takeda Pharmaceutical, CONTRAVE, naltrexone, bupropion

Nuviant Medical Names Brian Blischak Chief Commercial Officer

Tue, 03/15/2016 - 16:13
Key Hire positions Nuviant for accelerated growth DALLAS, March 15, 2016 /PRNewswire-iReach/ -- Nuviant Medical, Inc. ("Nuviant" or "the Company"), a medical device development and manufacturing company with proprietary closed-loop n...
Devices, Neurology, Personnel
Nuviant Medical, neuromodulation

Dutch Medical Center Begins Radiosurgery Treatments with Elekta's Leksell Gamma Knife Icon

Tue, 03/15/2016 - 16:10
Frameless, multisession Gamma Knife radiosurgery a new option at Tilburg hospital TILBURG, the Netherlands, March 15, 2016 -- (Healthcare Sales & Marketing Network) -- On January 11, the Gamma Knife Center at Elisabeth Tweesteden Ziekenhuis (ETZ, Tilb...
Devices, Oncology, Neurosurgery
Elekta, Leksell, Gamma Knife, radiosurgery, radiotherapy

Arterys Completes Series A Financing

Mon, 03/14/2016 - 13:52
Funding from Emergent Medical Partners, GE Ventures and Other Leading Venture Investors Validates Future of Medical Imaging Technology SAN FRANCISCO, March 14, 2016 -- (Healthcare Sales & Marketing Network) -- Arterys Inc., a privately-held company ded...
Devices, Radiology, Venture Capital
Arterys, imaging, ViosWorks

ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma

Mon, 03/14/2016 - 13:41
VANCOUVER, March 14, 2016 -- (Healthcare Sales & Marketing Network) - ProNAi Therapeutics, Inc. (DNAI), a clinical-stage oncology company advancing novel therapeutics for patients with cancer and hematological diseases, today announced that its oncology d...
Biopharmaceuticals, Oncology, FDA
ProNAi Therapeutics, PNT2258, Orphan Drug, lymphoma

The European Association of Urology Upgrades UroLift(R) System Trial Data to its Highest Possible Classification - Level 1A - in its Guidelines

Mon, 03/14/2016 - 13:31
Further evidence from two multi-national randomized studies presented at EAU conference supports durability of UroLift® System treatment for men with enlarged prostate MUNICH, March 14, 2016 -- (Healthcare Sales & Marketing Network) -- The UroLift ...
Devices, Urology
NeoTract, UroLift, Benign Prostatic Hyperplasia

Bantam Pharmaceutical Appoints Dr. Michael Luther President and CEO

Fri, 03/11/2016 - 13:50
NEW YORK, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Bantam Pharmaceutical, LLC, a pharmaceutical company focused on the discovery and development of compounds to treat cancer with a focus on RNA translation, today, announced that the com...
Biopharmaceuticals, Personnel
Bantam Pharmaceutical

Eigen USA and Hitachi Medical Systems Europe Switzerland Announce a Collaborative Agreement for Hitachi to Distribute the Artemis, Eigen's Robotic 3D Targeted Prostate Biopsy Device

Fri, 03/11/2016 - 13:43
The combined Hitachi Noblus and Artemis Eigen systems will be showcased at the European Association of Urology annual meeting in Munich, March 12th-14th, 2016, Booth #E16 ZUG, Switzerland, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Eig...
Devices, Oncology, Distribution
Hitachi Medical Systems, Artemis, Eigen, prostate biopsy

MedCom GmbH and Hitachi Medical Systems Europe Announce an Agreement to Distribute BiopSee(R), MedCom's Fusion Imaging System for Stereotactic, Navigated, Targeted Prostate Biopsy and Therapy Guidance, for use in Conjunction With Hitachi Ultrasound System

Fri, 03/11/2016 - 13:34
The combined Hitachi Noblus and MedCom BiopSee® systems will be showcased at the European Association of Urology (EAU) annual meeting in Munich, March 12th-14th, 2016, Booth #E16 ZUG, Switzerland, March 11, 2016 -- (Healthcare Sales & Marketing Netw...
Devices, Radiology, Oncology, Distribution
Hitachi Medical Systems, MedCom GmbH, BiopSee, prostate biopsy

HeartStitch, Inc. Appoints Renowned Cardiac Surgeon to Its Clinical Advisory Board

Fri, 03/11/2016 - 13:27
Dr. Yuriy Pya, Chief of Cardiac Surgery at the National Research Center for Cardiac Surgery, Kazakhstan's Top Cardiac Hospital, Joins HeartStitch(R) Clinical Advisory Board FOUNTAIN VALLEY, CA--(Healthcare Sales & Marketing Network) - HeartStitch®t...
Devices, Cardiology, Surgery, Personnel
HeartStitch, NobleStitch, vascular suture

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

Fri, 03/11/2016 - 13:13
TARRYTOWN, N.Y. and PARIS, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was sup...
Biopharmaceuticals
Regeneron Pharmaceuticals, Sanofi, sarilumab, rheumatoid arthritis

Revolutionary 3D Cardiac Mapping System Developed by Aurora Health Care Physician Receives FDA Clearance

Thu, 03/10/2016 - 14:58
MILWAUKEE, WI--(Healthcare Sales & Marketing Network) - Dr. Jasbir Sra, an internationally recognized cardiac electrophysiologist with Aurora Health Care, has received clearance from the Food and Drug Administration (FDA) to market a new three-dimensional ...
Devices, Cardiology, Radiology, FDA
Aurora Health Care, Navik 3D, cardiac mapping, atrial fibrillation

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong